MSB 7.69% $1.19 mesoblast limited

Ann: Mesoblast Partners with BMT CTN on Adult SR-aGVHD Trial, page-187

  1. 7,779 Posts.
    lightbulb Created with Sketch. 1337
    By performing the necessary experiments to get enough evidence of efficacy and potency that the FDA approves.

    By not doing so, by deliberately taking short cuts and failing, MSB is doing a disservice to these kids if the therapy actually works.

    It's simple.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.